22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Avadel Pharmaceuticals Plc › 2024-2025

Avadel Pharmaceuticals Plc 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Avadel Pharmaceuticals Plc’s Form 8-K, filed August 1, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 9Ballot items
  • 134Asset managers, any item
  • 349Fund votes
  • July 30, 2024Meeting date

Results at a glance

Meeting of July 30, 2024: 9 items on Avadel Pharmaceuticals Plc’s Form 8-K, filed August 1, 2024: 1 approved · 8 passed (calculated).

Dissent

Notable dissent: 1 director (10.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Avadel Pharmaceuticals Plc in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Avadel Pharmaceuticals Plc

These tallies are Avadel Pharmaceuticals Plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 1, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Avadel Pharmaceuticals Plc — official shareholder meeting results, meeting held July 30, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Gregory J. Divis 48,809,8084,581,316-- 37,58018,770,680 91%Passed (calculated)—
Elect Director: Dr. Eric J. Ende 47,813,6195,572,208-- 42,87718,770,680 90%Passed (calculated)—
Elect Director: Geoffrey M. Glass 48,119,0675,266,257-- 43,38018,770,680 90%Passed (calculated)—
Elect Director: Dr. Mark A. McCamish 48,811,3584,576,847-- 40,49918,770,680 91%Passed (calculated)—
Elect Director: Linda S. Palczuk 48,128,1735,258,040-- 42,49118,770,680 90%Passed (calculated)—
Elect Director: Peter J. Thornton 48,823,2824,562,281-- 43,14118,770,680 91%Passed (calculated)—
Elect Director: Dr. Naseem S. Amin 48,738,6544,646,143-- 43,90718,770,680 91%Passed (calculated)—
2. To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to authorize, in a binding vote, the Audit Comm 70,739,3851,299,493160,506 --0 98%Passed (calculated)—
3. To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement 47,961,5365,105,188361,980 --18,770,680 90%Approved—

Source: Avadel Pharmaceuticals Plc, Form 8-K, filed with the SEC on August 1, 2024 — read the filing on EDGAR.

How asset managers voted at the Avadel Pharmaceuticals Plc 2024-2025 meeting

134 asset managers disclosed a vote on at least one Avadel Pharmaceuticals Plc item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Dr. Eric J. Ende

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 47,813,619AGAINST: 5,572,208

Prior year: 99.0% for (August 1, 2023 meeting) ▼ 9.5 pts

Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Dr. Eric J. Ende

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Eric J. Ende”): 47,813,619 for, 5,572,208 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,804,656 for, 7,875 against.

FOR
FOR: 5,804,656AGAINST: 7,875
Largest asset managers voting on “Election of Directors: Dr. Eric J. Ende” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock04,190 00Against
State Street03,685 00Against
Portside Wealth Group, LLC1,4970 00For

Elect Director: Dr. Mark A. McCamish

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 48,811,358AGAINST: 4,576,847

Prior year: 99.9% for (August 1, 2023 meeting) ▼ 8.5 pts

Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Dr. Mark A. McCamish

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Mark A. McCamish”): 48,811,358 for, 4,576,847 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,812,531 for.

FOR
FOR: 5,812,531
Largest asset managers voting on “Election of Directors: Dr. Mark A. McCamish” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock4,1900 00For
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

Elect Director: Dr. Naseem S. Amin

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 48,738,654AGAINST: 4,646,143
Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Dr. Naseem S. Amin

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Naseem S. Amin”): 48,738,654 for, 4,646,143 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,812,531 for.

FOR
FOR: 5,812,531
Largest asset managers voting on “Election of Directors: Dr. Naseem S. Amin” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock4,1900 00For
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

Elect Director: Geoffrey M. Glass

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 48,119,067AGAINST: 5,266,257

Prior year: 99.5% for (August 1, 2023 meeting) ▼ 9.4 pts

Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Geoffrey M. Glass

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Geoffrey M. Glass”): 48,119,067 for, 5,266,257 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,808,341 for, 4,190 against.

FOR
FOR: 5,808,341AGAINST: 4,190
Largest asset managers voting on “Election of Directors: Geoffrey M. Glass” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock04,190 00Against
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

Elect Director: Gregory J. Divis

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 48,809,808AGAINST: 4,581,316

Prior year: 99.8% for (August 1, 2023 meeting) ▼ 8.3 pts

Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Gregory J. Divis

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Gregory J. Divis”): 48,809,808 for, 4,581,316 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,812,531 for.

FOR
FOR: 5,812,531
Largest asset managers voting on “Election of Directors: Gregory J. Divis” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock4,1900 00For
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

Elect Director: Linda S. Palczuk

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 48,128,173AGAINST: 5,258,040

Prior year: 99.9% for (August 1, 2023 meeting) ▼ 9.7 pts

Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Linda S. Palczuk

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Linda S. Palczuk”): 48,128,173 for, 5,258,040 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,808,341 for, 4,190 against.

FOR
FOR: 5,808,341AGAINST: 4,190
Largest asset managers voting on “Election of Directors: Linda S. Palczuk” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock04,190 00Against
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

Elect Director: Peter J. Thornton

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 48,823,282AGAINST: 4,562,281

Prior year: 99.8% for (August 1, 2023 meeting) ▼ 8.4 pts

Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: Election of Directors: Peter J. Thornton

Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Peter J. Thornton”): 48,823,282 for, 4,562,281 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 5,812,531 for.

FOR
FOR: 5,812,531
Largest asset managers voting on “Election of Directors: Peter J. Thornton” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock4,1900 00For
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 47,961,536AGAINST: 5,105,188
Details: description as filed, official tally, votes by 134 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.

Avadel Pharmaceuticals Plc’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement”): 47,961,536 for, 5,105,188 against — passed, per its Form 8-K filed August 1, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 19 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
RBB Fund Trust45,0540 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock4,1900 00For
State Street3,6850 00For

Fund voting reports, all 19 managers: 5,856,088 for.

Institutional-manager reports: 118 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Janus Henderson12,815,9460 00For
GENDELL JEFFREY L05,740,143 00Against
Vivo Capital, LLC3,972,0990 00For
BRAIDWELL LP2,776,5390 00For
RTW INVESTMENTS, LP1,397,5070 00For
UniSuper Management Pty Ltd948,9070 00For
Woodline Partners LP926,1090 00For
MPM BioImpact LLC883,2470 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.664,7380 00For
BRANDES INVESTMENT PARTNERS, LP659,9310 00For
Tri Locum Partners LP592,6990 00For
KENNEDY CAPITAL MANAGEMENT LLC541,2720 00For
Soleus Capital Management, L.P.478,2550 00For
NEW YORK STATE COMMON RETIREMENT FUND445,1910 00For
Utah Retirement Systems410,2840 00For
Samsara BioCapital, LLC384,7840 00For
Goldman Sachs351,7600 00For
Knott David M Jr333,0000 00For
DRIEHAUS CAPITAL MANAGEMENT LLC294,0770 00For
BALYASNY ASSET MANAGEMENT L.P.287,0080 00For
Candriam S.C.A.00 280,0000Abstain
Obermeyer Wealth Partners279,4940 00For
MARSHALL WACE, LLP248,1250 00For
LORD, ABBETT & CO. LLC232,2980 00For
Citadel230,9280 00For

Institutional-manager reports, all 118 managers: 32,094,720 for, 5,760,293 against, 285,686 abstained. Showing the 25 largest; every one is in the interactive database (link above).

To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 70,739,385AGAINST: 1,299,493

Prior year: 99.8% for (August 1, 2023 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 20 asset managers

Description as filed by funds: To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to authorize, in a binding vote, the Audit Committee of the Board of Directors to set the independent registered public auditor and accounting firm remuneration

Avadel Pharmaceuticals Plc’s own tally for this item (“2. To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to auth”): 70,739,385 for, 1,299,493 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 5,857,585 for.

FOR
FOR: 5,857,585
Largest asset managers voting on “To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independ” at Avadel Pharmaceuticals Plc, 2024-2025
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND4,629,1640 00For
DWS421,0000 00For
BRANDES INVESTMENT TRUST273,2020 00For
Lord Abbett85,5160 00For
Russell Investments63,3650 00For
DRIEHAUS MUTUAL FUNDS62,7530 00For
Fidelity45,6900 00For
RBB Fund Trust45,0540 00For
PENN SERIES FUNDS INC42,2580 00For
Royce35,4600 00For
RBB FUND, INC.34,0300 00For
AdvisorShares Trust31,7650 00For
Equitable30,6400 00For
Brinker Capital Destinations Trust21,6260 00For
TRUST FOR PROFESSIONAL MANAGERS12,6770 00For
Empower8,1200 00For
ProShares5,8930 00For
BlackRock4,1900 00For
State Street3,6850 00For
Portside Wealth Group, LLC1,4970 00For

Largest Avadel Pharmaceuticals Plc shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 96,204,000 shares outstanding at the time of that meeting.

Fund voting reports: top Avadel Pharmaceuticals Plc shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1JANUS INVESTMENT FUND 4.81%
2DWS 0.44%
3BRANDES INVESTMENT TRUST 0.28%
4Lord Abbett 0.09%
5Russell Investments 0.07%
6DRIEHAUS MUTUAL FUNDS 0.07%
7Fidelity 0.05%
8RBB Fund Trust 0.05%
9PENN SERIES FUNDS INC 0.04%
10Royce 0.04%
Institutional-manager reports: top Avadel Pharmaceuticals Plc shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Janus Henderson 13.32%
2GENDELL JEFFREY L 5.97%
3Vivo Capital, LLC 4.13%
4BRAIDWELL LP 2.89%
5RTW INVESTMENTS, LP 1.45%
6UniSuper Management Pty Ltd 0.99%
7Woodline Partners LP 0.96%
8MPM BioImpact LLC 0.92%
9ADAGE CAPITAL PARTNERS GP, L.L.C. 0.69%
10BRANDES INVESTMENT PARTNERS, LP 0.69%

Reported Avadel Pharmaceuticals Plc holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Avadel Pharmaceuticals Plc holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock5,453,526 5.67%Form 13F, quarter ended March 31, 2025
Jeffrey L. Gendell4,839,357 5.03%Schedule 13G, filed February 6, 2026
Vanguard Group3,904,650 4.06%Form 13F, quarter ended March 31, 2025
Citadel Advisors2,409,110 2.50%Form 13F, quarter ended March 31, 2025
JANUS HENDERSON GROUP PLC1,823,865 1.90%Schedule 13G, filed February 17, 2026
State Street1,659,306 1.72%Form 13F, quarter ended March 31, 2025
Geode Capital1,189,596 1.24%Form 13F, quarter ended March 31, 2025
Morgan Stanley1,034,614 1.08%Form 13F, quarter ended March 31, 2025
Goldman Sachs727,869 0.76%Form 13F, quarter ended March 31, 2025
Northern Trust639,866 0.67%Form 13F, quarter ended March 31, 2025

Percentages above are of 96,204,000 shares outstanding, as reported by Avadel Pharmaceuticals Plc on its Form 10-Q dated June 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Avadel Pharmaceuticals Plc's shareholder meeting held July 30, 2024, in the 2024-2025 proxy season, 134 asset managers reported votes on at least one of its 9 ballot items in their SEC Form N-PX filings, covering 349 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the named executive officers… — Avadel Pharmaceuticals Plc's filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Avadel Pharmaceuticals Plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 1, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Avadel Pharmaceuticals Plc’s 10-Q dated June 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Avadel Pharmaceuticals Plc proxy season coverage: 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Avadel Pharmaceuticals Plc 2024 Annual Meeting (2024-2025 season)”, https://proxyvotesnow.com/company/avadel-pharmaceuticals-plc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.